撤回：LAG3和PD1调节弥漫性大B细胞淋巴瘤患者的CD8 + T细胞。
Retracted: LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
作者信息
Methods In Medicine Computational And Mathematical
出版信息
Comput Math Methods Med. 2023 Sep 27;2023:9831240. doi: 10.1155/2023/9831240. eCollection 2023.
Abstract
[This retracts the article DOI: 10.1155/2021/4468140.].
摘要
[本文撤回文章DOI: 10.1155/2021/4468140。]
相似文献
1
Retracted: LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.撤回：LAG3和PD1调节弥漫性大B细胞淋巴瘤患者的CD8 + T细胞。
Comput Math Methods Med. 2023 Sep 27;2023:9831240. doi: 10.1155/2023/9831240. eCollection 2023.
2
LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.LAG3 和 PD1 调节弥漫大 B 细胞淋巴瘤患者的 CD8+ T 细胞。
Comput Math Methods Med. 2021 Aug 12;2021:4468140. doi: 10.1155/2021/4468140. eCollection 2021.
3
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.在小鼠卵巢癌模型中，LAG3和PD1共抑制分子协同作用，限制CD8 + T细胞信号传导并抑制抗肿瘤免疫。
Oncotarget. 2015 Sep 29;6(29):27359-77. doi: 10.18632/oncotarget.4751.
4
Association Between Expression Level of PD1 by Tumor-Infiltrating CD8 T Cells and Features of Hepatocellular Carcinoma.肿瘤浸润 CD8 T 细胞中 PD1 的表达水平与肝细胞癌特征的关系。
Gastroenterology. 2018 Dec;155(6):1936-1950.e17. doi: 10.1053/j.gastro.2018.08.030. Epub 2018 Aug 24.
5
LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma.LAG3：弥漫性大B细胞淋巴瘤中多种淋巴细胞亚群表达的新型免疫检查点。
Blood Adv. 2020 Apr 14;4(7):1367-1377. doi: 10.1182/bloodadvances.2019001390.
6
Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction.建立介导LAG3和PD1免疫抑制的工程细胞检测方法，可实现阻断抗体的效价测定和信号转导评估。
J Immunol Methods. 2018 May;456:7-14. doi: 10.1016/j.jim.2018.02.003. Epub 2018 Feb 8.
7
The multi-specific V-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.多特异性 V 基 Humabody CB213 共靶向 T 细胞上的 PD1 和 LAG3 以促进抗肿瘤活性。
Br J Cancer. 2022 May;126(8):1168-1177. doi: 10.1038/s41416-021-01684-4. Epub 2021 Dec 30.
8
Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.LAG3 在癌症治疗中的分子途径和机制。
Clin Cancer Res. 2022 Dec 1;28(23):5030-5039. doi: 10.1158/1078-0432.CCR-21-2390.
9
Retracted: Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.撤回：初治同时性滤泡性淋巴瘤和弥漫性大B细胞淋巴瘤不良预后因素筛查及预后指数构建
Biomed Res Int. 2023 Dec 29;2023:9816943. doi: 10.1155/2023/9816943. eCollection 2023.
10
Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors.解析双特异性抗体 PD1-TIM3 和 PD1-LAG3 在人类肿瘤中的体外分子和细胞反应。
J Immunother Cancer. 2022 Nov;10(11). doi: 10.1136/jitc-2022-005548.
本文引用的文献
1
LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.LAG3 和 PD1 调节弥漫大 B 细胞淋巴瘤患者的 CD8+ T 细胞。
Comput Math Methods Med. 2021 Aug 12;2021:4468140. doi: 10.1155/2021/4468140. eCollection 2021.
Zotero 插件